# Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

> **NCT00171301** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 233 (actual)

## Conditions studied

- Beta-thalassemia Major
- Hemosiderosis
- Iron Overload
- Rare Anemia

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT00171301
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2011-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171301, "Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00171301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*